Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Interv. 2008 Oct;8(5):230-41. doi: 10.1124/mi.8.5.8.

Looking at lithium: molecular moods and complex behaviour.

Author information

1
Department of Anatomy and Physiology, Université Laval/CRULRG, Québec, Canada G1J 2G3.

Abstract

Lithium and other mood-stabilizing drugs are used for the management of bipolar mood disorders and, to a lesser extent, for augmentation of other psychoactive drugs. Lithium also has neuroprotective properties that may be useful for treatment of neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis. Over the years, lithium has been shown to inhibit inositol monophosphatases and glycogen synthase kinase 3, but the relevance of such enzyme inhibition to the therapeutic effects of lithium has remained difficult to assess. Here, we provide an overview of recent advances in the identification of molecular mechanisms involved in the regulation of behavior by lithium. We also highlight recent findings suggesting that lithium could exert some of its behavioral effects by acting on a dopamine receptor regulated signaling complex composed of Akt, protein phosphatase 2A, and the multifunctional protein scaffold beta-arrestin 2.

PMID:
19015387
DOI:
10.1124/mi.8.5.8
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center